KO Client VitriVax Closes $17.25 Million Series B

KO client VitriVax, a vaccine formulation technology company, recently announced that it has completed a $17.25 million Series B financing.

The round was co-led by Adjuvant Capital and RA Capital Management and will advance VitriVax’s ALTA® thermostable vaccine platform and support the next phase of its clinical and regulatory journey.

“The completion of our Series B financing marks an important milestone for VitriVax as we continue to advance the development of ALTA®, our thermostable, single-shot vaccine platform,” said Romulo Colindres, Chief Executive Officer of VitriVax, in the announcement. “This funding positions us well to execute on our regulatory and clinical strategies, bringing us closer to addressing critical needs in vaccine access and immunization coverage.”

KO partner Jon Taylor and attorney Elizabeth Ho represented VitriVax in the financing. Read more in the press release, BioSpace, and more.